Validation of SFRP1 Promoter Hypermethylation in Plasma as a Prognostic Marker for Survival and Gemcitabine Effectiveness in Patients with Stage IV Pancreatic Adenocarcinoma

Validation of SFRP1 Promoter Hypermethylation in Plasma as a Prognostic Marker for Survival and Gemcitabine Effectiveness in Patients with Stage IV Pancreatic Adenocarcinoma

No reliable predictive blood-based biomarkers are available for determining survival from pancreatic adenocarcinoma (PDAC). This combined discovery and validation study examines promoter hypermethylation (ph) of secreted frizzled-related protein 1 (SFRP1) in plasma-derived cell-free DNA as an indepe...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Benjamin Emil Stubbe, Stine Dam Henriksen, Poul Henning Madsen, Anders Christian Larsen, Henrik Bygum Krarup, Inge Søkilde Pedersen, Martin Nygård Johansen, Ole Thorlacius-Ussing
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
biomarker
cancer
pancreatic cancer
prognostic
survival
blood-based
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/6057e4d7ae15449b8123c6666d98c261
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares